An Open-Label Multicenter Phase 1a Study of AN2025 and AN0025 in Double Combination with Atezolizumab and in Triple Combination with Atezolizumab in Patients with Advanced Solid Tumors.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Willing and able to comply with all aspects of the protocol. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 3. Life expectancy =3 months. 4. Diagnosed with histologically confirmed locally advanced and nonresectable, or metastatic disease. 5. Have received at least one line of prior systemic therapy or no alternative therapy to prolong survival exists. 6. Have received no more than 4 prior lines of systemic therapy for advanced disease. Prior therapy in an adjuvant or neoadjuvant setting is not considered as a prior line of systemic therapy.

You may not be eligible for this study if the following are true:

  • 1. Participants have been discontinued treatment due to a Grade 3 or higher immune-related AE (irAE) from prior anti-PD-1or anti-PD-L1, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137). 2. Have received prior systemic anti-cancer therapy including investigational agents within 4 weeks or 5 half-lives, whichever is shorter. Note: Participants must have recovered from all AEs due to previous therapies to = Grade 1 or returned to baseline. Participants with = Grade 2 neuropathy or alopecia may be eligible. Note: If a participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3. Have received prior palliative radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (= 2 weeks of radiotherapy) to non-CNS disease. 4. Severe, uncontrolled tumor-related pain.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.